Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [11C]CPPC PET ligand
CPPC PET ligand · 1 trial · 1 indication
Safety of use of \[11C\]CPPC in positron emission tomography (PET) neuroimaging of patients with a diagnosis of ALS. Safety will be assessed by number of adverse events during and up to 180 days after the injection
Safety of use of \[11C\]CPPC in positron emission tomography (PET) neuroimaging of patients with a diagnosis of ALS. Safety will be assessed by neurological physical exam to determine if there is a change in the findings from baseline.
Safety of use of \[11C\]CPPC in positron emission tomography (PET) neuroimaging of patients with a diagnosis of ALS. Safety will be assessed by monitoring of the complete blood count (CBC) for a change from baseline that is outside of the normal range.
Safety of use of \[11C\]CPPC in positron emission tomography (PET) neuroimaging of patients with a diagnosis of ALS. Safety will be assessed by a change in the CMP from baseline that is outside of the normal range.
| Arm | Type | Description |
|---|---|---|
| [11C]CPPC | EXPERIMENTAL | All participants will receive \[11C\]CPPC which is a radiotracer ligand that specifically binds to CSF1R. |
| Name | Type | Description |
|---|---|---|
| [11C]CPPC PET ligand | DRUG | Radioactive PET ligand to determine microglia expression of colony stimulating factor 1 receptor (CSF1R). |
Inclusion Criteria 1. Have the ability to understand the requirements of the study, provide written informed consent, understand and provide written authorization for the use and disclosure of Protected Health Information (PHI) \[per Health Insurance Portability and Accountability Act (HIPAA) Priva...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. | AMLX | 2 | PHASE3 | AMX0035 |
| Biogen Inc. | BIIB | 2 | PHASE3 | Tofersen |
| Ionis Pharmaceuticals, Inc. | IONS | 1 | PHASE3 | ION363 |
| Corcept Therapeutics Incorporated. | CORT | 1 | PHASE2 | Dazucorilant |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | VHB937 |
| argenx SE Sponsored ADR | ARGX | 1 | PHASE2 | ARGX-119 |
| MediciNova, Inc. | MNOV | 1 | PHASE2 | MN-166 |
| Coya Therapeutics, Inc. | COYA | 1 | PHASE2 | COYA 302 |
| Clene Inc | CLNN | 1 | PHASE2 | CNMAu8 |
| Eli Lilly and Company | LLY | 2 | PHASE1 | 89Zr-DFO-AP-101 |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | ALN-SOD |
| Insmed Incorporated | INSM | 1 | PHASE1 | INS1202 |
| uniQure N.V. | QURE | 1 | PHASE1 | AMT-162 |
| AC Immune SA | ACIU | 1 | EARLY_PHASE1 | Undisclosed |
| Design Therapeutics, Inc. | DSGN | 1 | - | Undisclosed |
CPPC PET ligand is an investigational small molecule being developed for use in amyotrophic lateral sclerosis (ALS). It is a positron emission tomography (PET) radioligand intended to serve as a clinical biomarker of microglial activation in ALS. The drug is currently in Phase 1 clinical development.
CPPC PET ligand is designed to target microglial activation, which is a biological process associated with neuroinflammation in ALS. As a PET radioligand, it is intended to enable visualization of this process in the brain using positron emission tomography imaging. The drug is being studied as a biomarker in ALS.
CPPC PET ligand is being developed by United Therapeutics Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol UTHR. The company is conducting a Phase 1 clinical trial of the drug in ALS patients.
CPPC PET ligand is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in an early-stage clinical trial to evaluate its use as a PET radioligand biomarker in ALS.
CPPC PET ligand is being studied in one Phase 1 clinical trial with the identifier NCT05602142. The trial is titled 'Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS' and is designed to enroll 20 participants with ALS. The trial is not yet recruiting.
Yes, CPPC PET ligand is also known as [11C]CPPC PET ligand. The two names refer to the same investigational drug, with the [11C] designation indicating the carbon-11 radioisotope used in the PET imaging agent. Both names are used in the clinical trial context.